Further investigations evaluating the potential of our degradative 3B12A intrabody against pathogenic TDP-43 using appropriate animal models are required to advance this novel molecular targeting therapy for ALS. The gene discussed is TARDBP; the disease is amyotrophic lateral sclerosis.